Business Standard

Bharat Biotech gets nasal vaccine nod for use as mix-match booster

iNCOVACC first intranasal Covid shot to receive approval for primary 2-dose schedule, heterologous booster us

Bharat Biotech's intranasal Covid vaccine
Premium

In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series

Sohini Das Mumbai
Bharat Biotech’s intranasal Covid-19 vaccine iNCOVACC has received the Indian drug regulator’s nod to be used as a heterologous booster (a mix-and-match dose after the primary dose). iNCOVACC has got approval for restricted use in emergency situations on those aged 18 years and above, for heterologous booster after two doses of either Covishield or Covaxin.

This nasal vaccine becomes the second-approved Covid-19 vaccine in India, after Biological E’s Corbevax, which can be used as a mix-and-match booster shot.

In September, the company received the Drugs Controller General of India’s (DCGI’s) approval for this vaccine, making it the second intranasal Covid-19

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 28 2022 | 9:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com